Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The liver-x-receptor/endothelial progenitor cell secretome: a new source of anti-atherogenic proteins

FY 2018-19

Summary
Heart disease is the leading cause of death worldwide, representing 31% of annual mortalities. A major contributing factor to heart disease is atherosclerosis, the hardening of arteries due to plaque buildup. Atherosclerosis begins when endothelial cells lining the artery become physically or chemically damaged. This induces endothelial dysfunction, which allows the accumulation of cholesterol and inflammatory cells within the arteries, leading to plaque formation. Cholesterol-rich plaques can rupture, creating blood clots that can cause a heart attack or stroke. Currently, the prevention of atherosclerosis is managed by statin drugs that reduce blood cholesterol levels. However, since cholesterol reduction does not fully prevent vascular complications, novel therapies targeting early atherosclerosis are urgently needed. The proposed project will study bone-marrow derived endothelial progenitor cells (EPCs) and investigate how enhancing EPC function can repair and protect endothelial cells during early atherosclerosis. Previous studies have shown that the activation of a nuclear protein, liver X receptor (LXR), reduces intracellular cholesterol levels in macrophages, a primary atherosclerotic inflammatory cell type. Interestingly, our lab recently found that LXR activation in murine EPCs causes these stem-like cells to secrete protective factors to decrease early plaque formation. We aim to reveal how LXRs interact with EPCs to elicit their protective role, identify which secreted factors contribute to the observed effects and determine its reproducibility in human EPCs. This project will enhance our understanding of the fundamental mechanisms by which EPCs support damaged endothelial cells during early atherogenesis, and identify potential new therapeutic targets.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406545
Name
Shawky Sarah A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The liver-x-receptor/endothelial progenitor cell secretome: a new source of anti-atherogenic proteins
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atherosclerosis; Cardiovascular Disease; Cellular Therapy; Cholesterol Efflux; Endothelial Progenitor Cell Secretome; Hematopoietic Stem Cells; Inflammatory Signaling; Liver X Receptors; Monocyte-Endothelial Cell Adhesion; Proteomics
Abstract
Heart disease is the leading cause of death worldwide, representing 31% of annual mortalities. A major contributing factor to heart disease is atherosclerosis, the hardening of arteries due to plaque buildup. Atherosclerosis begins when endothelial cells lining the artery become physically or chemically damaged. This induces endothelial dysfunction, which allows the accumulation of cholesterol and inflammatory cells within the arteries, leading to plaque formation. Cholesterol-rich plaques can rupture, creating blood clots that can cause a heart attack or stroke. Currently, the prevention of atherosclerosis is managed by statin drugs that reduce blood cholesterol levels. However, since cholesterol reduction does not fully prevent vascular complications, novel therapies targeting early atherosclerosis are urgently needed. The proposed project will study bone-marrow derived endothelial progenitor cells (EPCs) and investigate how enhancing EPC function can repair and protect endothelial cells during early atherosclerosis. Previous studies have shown that the activation of a nuclear protein, liver X receptor (LXR), reduces intracellular cholesterol levels in macrophages, a primary atherosclerotic inflammatory cell type. Interestingly, our lab recently found that LXR activation in murine EPCs causes these stem-like cells to secrete protective factors to decrease early plaque formation. We aim to reveal how LXRs interact with EPCs to elicit their protective role, identify which secreted factors contribute to the observed effects and determine its reproducibility in human EPCs. This project will enhance our understanding of the fundamental mechanisms by which EPCs support damaged endothelial cells during early atherogenesis, and identify potential new therapeutic targets.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shawky, Sarah A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~